1. Callery PS, Egorin MJ, Geelhaar LA, Nayar MSB (1986) Identification of metabolites of the cell-differentiating agent hexamethylene bisacetamide in humans. Cancer Res 46:4900
2. Chun H, Leyland-Jones B, Hoth D, Shoemaker D, Wolpert-DeFilippes M, Grieshaber C, Cradock J, Davignon P, Moon R, Rifkind R, Wittes RE (1986) Hexamethylene bisacetamide: a polar-planar compound entering clinical trials as a differentiating agent. Cancer Treat Rep 70:991
3. Collins SJ, Bodner A, Ting R, Gallo RC (1980) Induction of morphological and functional differentiation of human promyelocytic leukemia cells (HL-60) by compounds which induce differentiation of murine leukemia cells. Int J Cancer 25:213
4. Conley BA, Callery PS, Egorin MJ, Subramanyam B, Geelhaar L, Pan S (1988) Involvement of monoamine oxidase and diamine oxidase in the metabolism of the cell differentiating agent hexamethylene bisacetamide (HMBA). Life Sci 43:793
5. Conley BA, Forrest A, Egorin MJ, Zuhowski EG, Sinibaldi V, Van Echo DA (1989) Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580). Cancer Res 49:3436